Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics announced the U.K. High Court's approval of its redomiciliation to Delaware, USA, effective September 18, 2020. This process will establish Summit Therapeutics Inc. as the new holding company, with trading on Nasdaq under the ticker symbol SMMT beginning September 21, 2020. The redomiciliation does not change the share exchange ratio between the company's ordinary shares and American Depositary Shares. The company focuses on antibiotic innovation, particularly for Clostridioides difficile infections, currently testing its lead product, ridinilazole, in Phase III trials.
Summit Therapeutics plc has announced plans to redomicile its holding company from the UK to the US, aligning with its focus on US market operations. This change aims to enhance corporate flexibility and access to capital for its treatment, ridinilazole, targeting C. difficile infection. Under a court-approved scheme, existing shares will convert at a 5:1 ratio for new shares in Delaware-based 'New Summit.' Shareholder and court approvals are needed for this proposal, which will not affect UK operations in Oxford and Cambridge.
Summit Therapeutics plc announces the publication of Phase 2 clinical trial data for its antibiotic, ridinilazole, in the American Journal of Physiology – Gastrointestinal and Liver Physiology. The trial, which involved 100 patients, showed that ridinilazole preserved gut microbiome better than vancomycin, leading to a 60% reduction in C. difficile infection recurrence. Ridinilazole is designed to selectively target C. difficile while maintaining gut health, providing a stronger long-term clinical response.
Summit Therapeutics has appointed Michael Donaldson as its new Chief Financial Officer, effective immediately. Donaldson brings over 20 years of finance experience, especially in corporate finance. He previously held leadership positions at Goldfinch Bio and ARIAD Pharmaceuticals, contributing to significant acquisitions. The company's ongoing Phase 3 clinical trials for its antibiotic candidate, ridinilazole, hold promise for treating C. difficile infections. Summit aims to innovate in antibiotic development to improve patient outcomes while maintaining a focus on financial solutions.
Summit Therapeutics plc (NASDAQ: SMMT) reported its financial results for Q1 2020, highlighting a cash balance of $55.3 million as of March 31, down from $60.3 million at the end of 2019. The company posted a loss of $6.1 million, an improvement over the $6.9 million loss in Q1 2019. The Phase 3 Ri-CoDIFy clinical trials for ridinilazole have enrolled 291 patients as of May 31, 2020, though patient enrollment has been negatively affected by COVID-19 uncertainties, leading to the withdrawal of public commentary on trial completion timelines.
Summary not available.